Psychedelics biotech company Enveric Biosciences (NASDAQ:ENVB) provided a corporate update and reported financial results for the third quarter ended Sept. 30, 2024.

"The third quarter of 2024 was highlighted by important progress in the development of EB-003, our neuroplastogenic molecule that is designed to address difficult-to-treat mental health disorders without inducing the hallucinogenic effect common to N,N-Dimethyltryptamine (DMT) and related analogs," stated Joseph Tucker, Ph.D., director and CEO of Enveric. "Among the key achievements, data confirmed that EB-003 has the potential to be delivered via oral administration and penetrate the brain at levels expected to elicit the...